Home > Offer to Sell > Pharmaceuticals and Biochemicals > Others > MonoMethyl auristatin E/MMAE CAS:474645-27-7
MonoMethyl auristatin E/MMAE CAS:474645-27-7
Inquiry
| Post Date: | Aug 03,2017 |
| Expiry Date: | Aug 03,2018 |
| Detailed Description: |
Cas No. :474645-27-7
Quantity: 10mgFCL Price:145 USD FCL Payment Method: MoneyGram,Western Union，T/T MonoMethyl auristatin E MonoMethyl auristatin E;MMAE;Vedotin;MonoMethyl auristatin E(MMAE, vedotin);HM-297C-22;MonoMethyl auristatin E (MMAE);N-Methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide;N-Methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide Monomethyl CAS:474645-27-7 MF:C39H67N5O7 MW:717.97858 A Brief Introduction of MMAE(Monomethyl Auristatin E, Vedotin) What's MMAE? Monomethyl auristatin E (abbr. MMAE, commercial name as Vedotin) is a synthetic antineoplastic agent. It cannot be used as a drug itself due to its high toxicity, normally it is linked to a monoclonal antibody (MAB) which directs it to the cancer cells. Structure of MMAE: Please refer to: MMAE | Monomethyl Auristatin E MMAE is actually desmethyl-auristatin E; that is, the N-terminal amino group has only one methyl substituent instead of two as in auristatin E itself. Toxicity of MMAE: IC50 of proliferation/viability of tumor cell lines are in the range of 10-7-10-10 M for MMAF/ MMAE auristatin derivatives. MMAE mechanism of action: MMAE inhibits cell division by blocking the polymerisation of tubulin as antimitotic agent in ADCs(Antibody Drug Conjugates). FDA approved ADCs drugs with MMAE: Adcetris (brentuximab vedotin) is an ADC comprised of a chimeric anti-CD30 antibody (cAC10) conjugated through interchain disulfide bonds to monomethyl auristatin E (MMAE) via a valine-citrulline dipeptide cleavable linker, with an average DAR of 4.The FDA approval of Adcetris (brentuximab vedotin, Seattle Genetics) in 2011. Adcetris is an antibody-drug conjugate (ADC) directed to the protein CD30, which is expressed in classical Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). Commercial Availability of MMAE: MMAE is obtained from total synthesis and now available in the market. ALB Technology Limited is a professional ADCs drugs and linkers supplier. ALB Technology Limited provides ADCs products include |
| CAS Registry Number: | 474645-27-7 |
| Synonyms: | ;MMAE; |
| Company: | Wuhan Deme chem Biotechnology Co., Ltd [ China ] |
| Contact: | celia |
| Tel: | +8618942921723 |
| Fax: | +86-027-50458986 |
| Email: | wzh@dmksw.xin |
-
Disclaimer statement:The information and data included above have been realized by the enterprises and compiled by the staff, and are subject to change without notice to you. The Chemnet makes no warranties or representations whatsoever regarding the facticity, accuracy and validity of such information and data. In order to ensure your interest, we suggest you chose the products posted by our gold suppliers or VIP members.
